ADAMS ADRIAN 4
4 · Akebia Therapeutics, Inc. · Filed Jun 22, 2026
Research Summary
AI-generated summary of this filing
Akebia (AKBA) Director Adrian Adams Receives Awards
What Happened Adrian Adams, a director of Akebia Therapeutics (AKBA), received two awards on June 17, 2026: 35,700 restricted stock units (RSUs) and a derivative award in the form of a stock option covering 53,600 shares. Both grants are reported at $0.00 (standard for compensation grants), for a combined potential of 89,300 shares. These are awards/compensation — not open-market purchases or sales.
Key Details
- Transaction date: 2026-06-17; Report filed: 2026-06-22 (appears to be filed after the typical 2-business-day Form 4 deadline).
- Grants: 35,700 RSUs @ $0.00; 53,600-share stock option (derivative) @ $0.00.
- Vesting: Both awards vest 100% on the first anniversary of the grant (or immediately prior to the first annual meeting if earlier), subject to continuous service (per footnotes/F1 and F2).
- Plan and program: Awards granted under the Issuer’s 2023 Stock Incentive Plan and the Fifth Amended and Restated Non‑Employee Director Compensation Program.
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Filing timeliness: Reported five calendar days after the grants; appears late versus the usual 2-business-day Form 4 requirement (late filings reduce timely transparency).
Context RSUs convert to shares when they vest; the stock option is a grant giving the right to buy shares in the future if exercised (this filing documents the grant, not an exercise or sale). Director awards are common as part of non-employee director compensation and do not by themselves indicate a buy or sell decision in the market.
Insider Transaction Report
- Award
Common Stock
[F1]2026-06-17+35,700→ 236,200 total - Award
Stock Option (Right to buy)
[F2]2026-06-17+53,600→ 53,600 totalExercise: $1.02From: 2027-06-17Exp: 2036-06-17→ Common Stock (53,600 underlying)
Footnotes (2)
- [F1]The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date.
- [F2]The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date.